IMC Chicago’s ImmunityBio IBRX Stock Holding History

IMC Chicago’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.19M	Buy	338,000 +149,900	+80%	+$1.2M	﹤0.01%	2687
2026 Q2	$1.65M	Sell	188,100 -65,300	-26%	-$494K	﹤0.01%	3262
2026 Q1	$1.94M	Buy	+253,400	New	+$1.73M	﹤0.01%	2601

Other funds holding IBRX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Clearwater Capital Advisors Hoffman Estates, Illinois $1.39B AUM 12.56% 1-Year Est. Return

Allen Holding New York $1.15B AUM 24.01% 1-Year Est. Return

Kercheville Advisors San Antonio, Texas $361M AUM 57.53% 1-Year Est. Return

D.A. Davidson & Co Great Falls, Montana $18.6B AUM 17.65% 1-Year Est. Return

IMC Chicago's IBRX Position: Q3 2026 in Review

IMC Chicago sold out of ImmunityBio (IBRX) in Q3 2026, closing a stake of 53,011 shares — an estimated $424K sold.

IMC Chicago first reported a position in IBRX in Q1 2026 and held it in 2 quarters. The position peaked at $745K in Q1 2026. 192 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

IMC Chicago reported no remaining ImmunityBio position as of Q3 2026 after selling out during the quarter.
IMC Chicago sold 53,011 ImmunityBio shares in Q3 2026, an estimated $424K.
IMC Chicago first reported a position in ImmunityBio in Q1 2026 and held it in 2 quarters.
IMC Chicago's ImmunityBio position peaked at $745K in Q1 2026.
192 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.